Dr. Stanley J. Watowich
Biography & Research Background
Stanley J. Watowich, PhD, is Associate Professor in the Department of Biochemistry & Molecular Biology at the University of Texas Medical Branch (UTMB) at Galveston. He led the research team that identified 5-Amino 1MQ as a selective NNMT inhibitor, conducted the proof-of-concept obesity reversal studies in diet-induced obese mice, and founded Ridgeline Therapeutics to advance the compound toward FDA approval. He is the primary inventor on multiple U.S. patents for quinoline-derived NNMT inhibitors (US 11,401,243; US 12,071,409). Stanley J. Watowich is being referenced as one of the leading scientists involved in the research and development of 5-Amino-1MQ. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Stanley J. Watowich is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Stanley J. Watowich is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.